Nyxoah (NASDAQ:NYXH) Rating Reiterated by HC Wainwright

HC Wainwright restated their buy rating on shares of Nyxoah (NASDAQ:NYXH) in a report released on Wednesday, Benzinga reports. The firm currently has a $18.00 target price on the stock. HC Wainwright also issued estimates for Nyxoah’s Q3 2024 earnings at ($0.50) EPS, Q4 2024 earnings at ($0.49) EPS, FY2024 earnings at ($1.92) EPS, FY2025 earnings at ($1.42) EPS and FY2026 earnings at $0.15 EPS.

A number of other analysts also recently commented on the company. Oppenheimer decreased their target price on Nyxoah from $20.00 to $15.00 and set an outperform rating on the stock in a research report on Wednesday, May 15th. Cantor Fitzgerald cut their target price on shares of Nyxoah from $18.00 to $17.00 and set an overweight rating for the company in a research report on Wednesday, May 15th. Finally, Stifel Nicolaus reduced their price target on shares of Nyxoah from $27.00 to $19.00 and set a buy rating on the stock in a report on Monday, June 24th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has a consensus rating of Buy and a consensus target price of $17.20.

Nyxoah Price Performance

Shares of NASDAQ NYXH traded up $0.20 during trading on Wednesday, hitting $8.54. 5,170 shares of the company were exchanged, compared to its average volume of 44,131. The firm’s fifty day moving average price is $8.34 and its 200 day moving average price is $10.62. The company has a debt-to-equity ratio of 0.13, a current ratio of 3.94 and a quick ratio of 3.70. The company has a market cap of $212.99 million, a price-to-earnings ratio of -5.21 and a beta of 1.44. Nyxoah has a 1 year low of $4.00 and a 1 year high of $20.00.

Nyxoah (NASDAQ:NYXH) last released its quarterly earnings data on Tuesday, May 14th. The company reported ($0.45) EPS for the quarter, hitting analysts’ consensus estimates of ($0.45). Nyxoah had a negative net margin of 843.49% and a negative return on equity of 42.14%. The firm had revenue of $1.33 million for the quarter, compared to the consensus estimate of $1.20 million. On average, sell-side analysts expect that Nyxoah will post -1.72 earnings per share for the current fiscal year.

Institutional Trading of Nyxoah

An institutional investor recently bought a new position in Nyxoah stock. Ikarian Capital LLC purchased a new position in shares of Nyxoah S.A. (NASDAQ:NYXH) during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 50,699 shares of the company’s stock, valued at approximately $684,000.

About Nyxoah

Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company's lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea.